Future agents and treatment directions in multiple myeloma.

Abstract

The development of bortezomib and immunomodulatory agents resulted in a revolution in the treatment of multiple myeloma (MM). Moreover, second-generation proteasome inhibitors (carfilzomib) and immunomodulatory agents (pomalidomide) have recently been approved. Nevertheless, the incurability of this disease requires other drugs with different mechanisms of… (More)
DOI: 10.1586/17474086.2014.858595

Topics

Cite this paper

@article{Ocio2014FutureAA, title={Future agents and treatment directions in multiple myeloma.}, author={Enrique Mar{\'i}a Ocio and Constantine Mitsiades and Robert Z. Orlowski and Kenneth C. Anderson}, journal={Expert review of hematology}, year={2014}, volume={7 1}, pages={127-41} }